Cargando...
Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma
Indolent CNS lymphomas (CNSLs) are rare and no guidelines exist for management. Recent literature highlights the potential for safe and tolerable intrathecal (IT) delivery of rituximab, a large anti-CD20 monoclonal antibody, for aggressive CNSL. We report a patient with relapsed indolent CNSL who fa...
Gardado en:
| Publicado en: | CNS Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Future Medicine Ltd
2015
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4778415/ https://ncbi.nlm.nih.gov/pubmed/25905905 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/cns.15.3 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|